Increase in antibody-dependent cellular cytotoxicity (ADCC) in a patient with advanced colorectal carcinoma carrying a KRAS mutation under lenalidomide therapy

Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials

(2013) J. D. Wolchok et al.   ANNALS OF ONCOLOGY

Oncogenic RAS simultaneously protects against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR signaling blockade

(2012) S Kasper et al.   ONCOGENE

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Epidermal Growth Factor Receptor (EGFR) Antibody-Induced Antibody-Dependent Cellular Cytotoxicity Plays a Prominent Role in Inhibiting Tumorigenesis, Even of Tumor Cells Insensitive to EGFR Signaling Inhibition

(2011) M. B. Overdijk et al.   JOURNAL OF IMMUNOLOGY

Initial testing of lenalidomide by the pediatric preclinical testing program

(2011) C. Patrick Reynolds et al.   PEDIATRIC BLOOD & CANCER

Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo

(2011) J.Y. Henry et al.   PROSTATE

Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers

(2010) Lei Wu et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo

(2009) Liang Zhang et al.   AMERICAN JOURNAL OF HEMATOLOGY

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH

Immunomodulatory drugs Revlimid® (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation

(2008) Dan Zhu et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors

(2008) Sharon L. Sanborn et al.   INVESTIGATIONAL NEW DRUGS